Search Result
Results for "
acidic-pH
" in MedChemExpress (MCE) Product Catalog:
8
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P2863
-
DNase II
|
Endonuclease
|
Others
|
Deoxyribonuclease II (DNase II) is an endonuclease that hydrolyzes the phosphodiester bonds of deoxyribonucleotides in native and denatured DNA, producing 3' phosphate and 5'-hydroxyl termini. Deoxyribonuclease II works best at acidic pH and is commonly used in biochemical research .
|
-
-
- HY-B1329
-
Nebramycin II sulfate
|
Bacterial
Antibiotic
|
Infection
|
Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-W039911
-
PNP-alpHa-D-Gal; PNP-α-D-Gal
|
Biochemical Assay Reagents
|
Others
|
4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside for detecting α-galactosidase activity. The amount of released pNP is significantly increased when 4-Nitrophenyl α-D-galactopyranoside is used as substrates .
|
-
-
- HY-167003
-
|
Liposome
|
Others
|
L16 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. L16 can be used in the preparation of liposomes .
|
-
-
- HY-167004
-
|
Liposome
|
Others
|
IAJD93 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD93 can be used in the preparation of liposomes .
|
-
-
- HY-167004A
-
|
Liposome
|
Others
|
IAJD249 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD249 can be used in the preparation of liposomes .
|
-
-
- HY-167002
-
|
Liposome
|
Others
|
RM 137-15 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. RM 137-15 can be used in the preparation of liposomes .
|
-
-
- HY-167011
-
|
Liposome
|
Others
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
-
- HY-167015
-
|
Liposome
|
Others
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
-
- HY-167012
-
|
Liposome
|
Others
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
-
-
- HY-128144
-
|
Lipase
|
Metabolic Disease
|
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .
|
-
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
-
- HY-P0041
-
-
-
- HY-P0041A
-
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-P5161A
-
|
GCGR
|
Metabolic Disease
|
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
|
-
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-113560
-
-
-
- HY-P1162
-
-
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-W039911
-
PNP-alpHa-D-Gal; PNP-α-D-Gal
|
Enzyme Substrates
|
4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside for detecting α-galactosidase activity. The amount of released pNP is significantly increased when 4-Nitrophenyl α-D-galactopyranoside is used as substrates .
|
-
- HY-167003
-
|
Drug Delivery
|
L16 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. L16 can be used in the preparation of liposomes .
|
-
- HY-167004
-
|
Drug Delivery
|
IAJD93 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD93 can be used in the preparation of liposomes .
|
-
- HY-167004A
-
|
Drug Delivery
|
IAJD249 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD249 can be used in the preparation of liposomes .
|
-
- HY-167002
-
|
Drug Delivery
|
RM 137-15 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. RM 137-15 can be used in the preparation of liposomes .
|
-
- HY-167011
-
|
Drug Delivery
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
- HY-167015
-
|
Drug Delivery
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
- HY-167012
-
|
Drug Delivery
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4116
-
pHLIP
|
Peptides
|
Metabolic Disease
Cancer
|
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .
|
-
- HY-P4116A
-
pHLIP TFA
|
Peptides
|
Metabolic Disease
Cancer
|
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .
|
-
- HY-P10218A
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0041A
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P10218
-
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P10318
-
|
GLP Receptor
|
Endocrinology
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P4837
-
|
Peptides
|
Others
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P10200
-
|
Bacterial
|
Infection
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P5161A
-
|
GCGR
|
Metabolic Disease
|
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .
|
-
- HY-P5161
-
-
- HY-P10271
-
|
GLP Receptor
|
Metabolic Disease
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50?of 7.68?nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST?and SPR assays, respectively.?BMSpep-57?facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68?nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P10341
-
|
GCGR
|
Metabolic Disease
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P10381
-
|
Peptides
|
Others
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
-
- HY-P4146A
-
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P4146
-
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-113560
-
-
- HY-P1162
-
-
- HY-P2595
-
|
Peptides
|
Cardiovascular Disease
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10031
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 displays high potency with balanced activation of all three target receptors.?SAR441255 shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P10031A
-
|
GLP Receptor
GCGR
|
Metabolic Disease
|
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors. SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys .
|
-
- HY-P4895
-
|
Oxytocin Receptor
|
Neurological Disease
|
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease .
|
-
- HY-P10272
-
PTG-300
|
Ferroportin
|
Others
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P10563
-
BHV-1100
|
CD38
|
Cancer
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
|
Classification |
-
- HY-167011
-
|
|
Cationic Lipids
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
- HY-167015
-
|
|
Cationic Lipids
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
- HY-167012
-
|
|
Cationic Lipids
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: